Company profile

Incorporated in
Fiscal year end
IRS number

ABBV stock data



3 May 19
17 Jun 19
31 Dec 19


Company financial data Financial data

Quarter (USD) Mar 19 Dec 18 Sep 18 Jun 18
Revenue 7.83B 8.31B 8.24B 8.28B
Net income 2.46B -1.83B 2.75B 1.98B
Diluted EPS 1.65 -1.23 1.81 1.26
Net profit margin 31.37% -21.99% 33.35% 23.96%
Operating income 3.01B -2.44B 3.16B 2.76B
Net change in cash -2.39B -726M 4.47B -5.46B
Cash on hand 4.9B 7.29B 8.02B 3.55B
Cost of revenue 1.69B 2.02B 1.84B 1.93B
Annual (USD) Dec 18 Dec 17 Dec 16 Dec 15
Revenue 32.75B 28.22B 25.64B 22.86B
Net income 5.69B 5.31B 5.95B 5.14B
Diluted EPS 3.66 3.3 3.63 3.13
Net profit margin 17.36% 18.82% 23.22% 22.50%
Operating income 6.38B 9.55B 9.34B 7.54B
Net change in cash -2.01B 4.2B -3.3B 51M
Cash on hand 7.29B 9.3B 5.1B 8.4B
Cost of revenue 7.72B 7.04B 5.83B 4.5B

Financial data from AbbVie earnings reports

Content analysis ?
8th grade Avg
New words: affirmed, Alvogen, AML, arm, BELLINI, Brook, Brown, coordinated, decision, delivery, encompassing, equipment, estate, giant, implicit, incremental, index, indirect, maintenance, Master, monitor, multiplied, Natco, petition, phototherapy, Pine, portfolio, proportion, psoriatic, published, real, renewal, SKYRIZI, stop, Sublease, tablet, TAHOE, tolerability, voluntarily, working
Removed: accelerated, added, adjust, administered, Agency, agent, antagonist, Arabia, atopic, Authorisation, authorized, award, awarded, background, Biogen, BLA, calculation, cancer, closely, collect, collectability, collection, complexity, concurrent, consolidation, consulting, core, Create, created, creating, Crohn, customary, customer, decrease, demonstrated, dependent, depict, disaggregation, domestic, dosing, doubtful, eighteen, elagolix, eligible, EMA, employer, endpoint, entitled, establish, experienced, extended, fully, geography, GnRH, good, Greece, grew, half, handling, Hedging, hormone, identification, implementing, Improving, incur, indemnified, induction, inventory, investee, investigate, investigated, Italy, jury, lag, launch, legislation, liable, licensing, lung, MAA, macroglobulinemia, magnitude, make, mandatory, Medicare, medicine, methotrexate, moderately, monotherapy, MURANO, negligence, neurology, originally, pathway, pay, payer, Pension, periodically, placebo, Portugal, Postretirement, potentially, preliminary, prepaid, prescription, primary, profile, promised, provisional, publicized, ranked, rebate, receptor, recovered, refractory, relapsed, relapsing, remeasurement, rendered, repatriation, require, requiring, resolved, response, rest, Retirement, retrial, retrospectively, Rituxan, rituximab, rovalpituzumab, Russia, sale, Saudi, SCLC, secondary, separately, Shilpa, shipment, shipping, significantly, small, sourced, Spain, stable, strict, submitted, Subtopic, superseded, taxability, taxation, territorial, tesirine, Teva, transferred, treat, TRINITY, unavailable, untaxed, ustekinumab, uterine, vacated, variation, vary, verdict, vi, VIEKIRA, volume, voluntary, withdrawal, ZINBRYTA